University of Kentucky/Markey Cancer Center
Claim this profile,
Global Leader in Skin Cancer
Global Leader in Uterine Tumors
Conducts research for Relapse
Conducts research for Lung Cancer
Conducts research for Cancer
540 reported clinical trials
33 medical researchers
Summary
University of Kentucky/Markey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Skin Cancer, Uterine Tumors, Relapse, Lung Cancer, Cancer and other specialties. University of Kentucky/Markey Cancer Center is involved with conducting 540 clinical trials across 622 conditions. There are 33 research doctors associated with this hospital, such as James T. Badgett, Susanne Arnold, MD, John Villano, MD, PhD, and Zin W. Myint.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Uterine Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
James T. BadgettUniversity of Kentucky/Markey Cancer Center7 years of reported clinical research
Expert in Uterine Tumors
Expert in T-Lymphoblastic Leukemia/Lymphoma
47 reported clinical trials
98 drugs studied
Susanne Arnold, MDUniversity of Kentucky/Markey Cancer Center2 years of reported clinical research
Expert in Skin Cancer
Expert in Lung Cancer
39 reported clinical trials
76 drugs studied
John Villano, MD, PhDUniversity of Kentucky/Markey Cancer Center6 years of reported clinical research
Studies Brain Tumor
Studies Lung Cancer
21 reported clinical trials
37 drugs studied
Zin W. MyintUniversity of Kentucky/Markey Cancer Center4 years of reported clinical research
Studies Skin Cancer
Studies Prostate Cancer
14 reported clinical trials
28 drugs studied
Clinical Trials running at University of Kentucky/Markey Cancer Center
Breast Cancer
Skin Cancer
Lung Cancer
Bladder Cancer
Cancer
Uterine Tumors
Pancreatic Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Breast cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Kentucky/Markey Cancer Center?
University of Kentucky/Markey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Skin Cancer, Uterine Tumors, Relapse, Lung Cancer, Cancer and other specialties. University of Kentucky/Markey Cancer Center is involved with conducting 540 clinical trials across 622 conditions. There are 33 research doctors associated with this hospital, such as James T. Badgett, Susanne Arnold, MD, John Villano, MD, PhD, and Zin W. Myint.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.